---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-056863"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T12:11:57.020580+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics names Monic Stuart, M.D., as new CMO; she brings 20+ years drug development experience

## Summary
- Dr. Stuart appointed CMO effective May 8, 2023; will oversee multiTAA-specific T cell pipeline including MT-401 Phase 2 ARTEMIS study.
- Over 20 years experience; previously interim CMO at multiple biotechs, VP Clinical Development at Geron, Senior Medical Director at Genentech.
- She is a transplant physician with expertise in AML and lymphoma, aligning with Marker's prioritized clinical programs.
- Dr. Stuart will lead clinical strategy for MT-401 in AML and MT-601 in non-Hodgkin lymphoma and pancreatic cancer.
- CEO Juan Vera cited her deep industry experience and clinical background as key to advancing pipeline.

## SEC filing metadata
- accession: 0001104659-23-056863
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465923056863/0001104659-23-056863-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465923056863/tm2314958d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-056863
- JSON: https://secwatch.observer/filing/0001104659-23-056863.json
- Plain text: https://secwatch.observer/filing/0001104659-23-056863.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.